Beta Finch - Healthcare & Devices - EN

Cigna Q1 2026 Earnings Analysis

**BETA FINCH PODCAST SCRIPT** --- ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and joining me as always is my co-host Jordan. Today we're diving into Cigna Group's Q1 2026 earnings call - and wow, there's a lot to unpack here, including some major leadership changes and strategic pivots. But before we jump in, I need to share an important disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: Thanks Alex. And speaking of major changes, this earnings call was pretty historic - it was CEO David Cordani's final quarterly call after 17 years leading the company. But the numbers certainly gave him a strong send-off. ALEX: Absolutely! So let's start with the headline numbers. Cigna reported Q1 revenue of $68.5 billion and adjusted EPS of $7.79. That EPS represents 16% year-over-year growth, which is pretty impressive. And based on this strong performance, they raised their full-year 2026 EPS guidance to at least $30.35. JORDAN: What's interesting is that both of their main segments - Evernorth and Cigna Healthcare - performed above internal expectations. Evernorth earnings were slightly ahead, while Cigna Healthcare really exceeded expectations with 18% earnings growth year-over-year. The medical care ratio came in at 79.8%, which was better than their guidance of slightly below 81%. ALEX: Now Jordan, there were some significant strategic announcements that I think investors need to pay attention to. Can you walk us through those? JORDAN: Sure thing. Cigna made two big portfolio moves. First, they're planning to exit the individual exchange business at the end of 2026. This isn't a huge surprise - it's been a small and shrinking business for them. CEO-elect Brian Evanko said they couldn't see a clear path to scale it meaningfully within Cigna's overall size. The second move is potentially bigger - they announced a strategic review for eviCore, which handles prior authorization services for multiple health plans. This seems to be driven by the industry's progress on standardizing and automating prior authorization processes. ALEX: And these moves really fit into their broader strategy of portfolio shaping, right? They're focusing resources on their three core growth platforms. JORDAN: Exactly. Evanko outlined those three platforms clearly: Specialty and Care Services, which represents about 35% of company income and is growing 8-12% annually; Pharmacy Benefit Services at about 25% of income; and Cigna Healthcare at 40% of income. They're essentially doubling down on what's working and shedding what isn't. ALEX: Let's talk about that specialty business because it really shone this quarter. Specialty and Care Services earnings grew 20% to $1.1 billion. What's driving that? JORDAN: Three main factors. First, solid specialty volume growth across the board. Second - and this is interesting - continued adoption of biosimilars and specialty generics. These deliver savings to patients while actually improving margins for Cigna. Third, they're getting contributions from their investment in Shields Health Solutions, which they made late last year. David Cordani specifically highlighted how they're using AI to improve biosimilar conversions. For drugs like Humira and Stelara, they're offering $0 out-of-pocket costs to patients while using AI to identify personalized conversion strategies. It's a win-win - lower costs, higher patient satisfaction, and better margins. ALEX: That ties into something Brian Evanko emphasized about the future - this focus on AI and data analytics. He's clearly putting his stamp on the company's direction. JORDAN: Right. When he takes over as CEO in July, Evanko outlined three areas of intensification: better use of data and AI for personalized care, drivin This episode includes AI-generated content.

Stryker Q1 2026 Earnings Analysis

**Beta Finch Podcast Script - Stryker Q1 2026 Earnings** --- **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we cut through the noise to bring you what really matters from corporate America's quarterly reports. I'm Alex. **JORDAN:** And I'm Jordan. Today we're diving into Stryker's Q1 2026 results, and wow, this was definitely not your typical earnings call. **ALEX:** Before we get into it, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. **JORDAN:** Absolutely. So Alex, let's start with the elephant in the room - Stryker got hit by a cyberattack late in Q1. How bad was the damage? **ALEX:** It was significant, Jordan. Organic sales growth came in at just 2.4% - way below what you'd normally expect from Stryker. Even more telling, adjusted earnings per share dropped 8.5% to $2.60. CEO Kevin Lobo mentioned they had 40,000 laptops wiped and were essentially shut down for about three weeks. **JORDAN:** That's brutal. But here's what caught my attention - despite all this chaos, they maintained their full-year guidance. That's either incredibly optimistic or they have serious confidence in their recovery plan. **ALEX:** I'm leaning toward confidence. CFO Preston Wells was pretty detailed about why they think they'll bounce back. He explained that different business units were affected differently based on their operating models. For example, their orthopedic business has a lot of consigned inventory sitting right at hospitals, so surgeries could continue even when Stryker's systems were down. **JORDAN:** Right, it was more of a revenue recognition issue there rather than lost procedures. But their capital equipment business - things like hospital beds and defibrillators - that's where they really got hit because those are made-to-order products. **ALEX:** Exactly. And Wells said most of that lost production will shift to Q3 and Q4 rather than Q2, which makes sense given manufacturing lead times. What I found interesting was how resilient their underlying business seems to be. **JORDAN:** Talk about that resilience - what are the bright spots? **ALEX:** Well, they had their best-ever Q1 for Mako robot installations, both in the US and internationally. That's their surgical robotics platform, and utilization rates are climbing. Plus they just got European approval for Pangaea - that's their trauma plating system that's been driving explosive growth in the US. **JORDAN:** And let's not forget the M&A activity. They announced they're acquiring Amplitude Vascular Systems, which gets them into the intravascular lithotripsy space. That's basically using sound waves to break up calcified plaque in blood vessels. **ALEX:** Kevin Lobo was really bullish on that deal during the Q&A. He said it fits perfectly with their existing peripheral vascular business through Inari, which they bought last year. Same call points, same physicians. **JORDAN:** Speaking of the Q&A, there were some great nuggets in there. One analyst asked about competitive dynamics in orthopedics, and Lobo basically said "bring it on." He mentioned they expect to keep outgrowing the orthopedic market by 200 to 300 basis points, just like they have been. **ALEX:** I loved his comment about their robotics portfolio too. He said the new Mako RPS - that's their handheld robotic system - is getting great feedback, especially in ambulatory surgery centers. It's like a stepping stone for surgeons who find full Mako too intimidating. **JORDAN:** The international story is pretty compelling too. While the US grew 1.9%, international was up 3.9% despite the cyber issues. Lobo highlighted Japan as their second-largest market outside the US, and it's experiencing "tremendous growth." **ALEX:** And they're just getting This episode includes AI-generated content.

Thermo Fisher Scientific Q1 2026 Earnings Analysis

**BETA FINCH PODCAST SCRIPT** ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we decode the numbers that matter. I'm Alex. JORDAN: And I'm Jordan. Today we're diving into Thermo Fisher Scientific's Q1 2026 earnings, and let me tell you, this one's got some interesting moving parts. ALEX: Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: Absolutely. So Alex, TMO just reported their first quarter results, and on the surface, it looks like a pretty solid performance. What caught your attention first? ALEX: Well, the headline numbers are decent but not spectacular. Revenue grew 6% to $11.01 billion, and adjusted EPS came in at $5.44, also up 6%. But here's the kicker - they actually beat their own guidance by 14 cents per share on the earnings side. JORDAN: That's a nice beat. And they're raising full-year guidance too, right? New revenue range of $47.3 to $48.1 billion, up from the previous $46.3 to $47.2 billion range. ALEX: Exactly. And on earnings, they're now expecting $24.64 to $25.12 per share, up from their original $24.22 to $24.80 guide. That represents 8% to 10% growth for the year. But Jordan, there's a big asterisk here - a lot of this guidance raise comes from their massive Clario acquisition. JORDAN: Right, the $9 billion elephant in the room. They closed that deal in late March. Clario is a digital endpoint data solutions company that complements their clinical research business. Even though it was only in the results for a few days, it contributed $30 million in revenue and a penny per share to Q1. ALEX: And CEO Marc Casper was pretty excited about it on the call. He kept talking about how it enhances their "trusted partner status" with pharma and biotech customers. The integration seems to be going smoothly, and customers are apparently enthusiastic about combining Thermo's capabilities with Clario's digital endpoints technology. JORDAN: Speaking of pharma and biotech, that was actually their strongest end market in the quarter with mid-single digit growth. Casper highlighted strength in bioproduction and clinical research. But let's talk about the headwinds they're facing. ALEX: Yeah, this is where it gets interesting. They had some real operational challenges. First, they had one less selling day compared to last year, which dinged organic growth by about a percentage point. Then there was revenue phasing in pharma services - another roughly one-point headwind. JORDAN: So if you normalize for those factors, their 1% organic growth in Q1 would have been closer to 3%. And that's exactly what they're guiding for in Q2. The concern from analysts on the call was about this acceleration they need in the back half of the year to hit their full-year 3-4% organic growth target. ALEX: Casper seemed pretty confident though. He said the markets are playing out exactly as expected, and the ramp isn't really assuming any change in underlying market conditions. It's more about these timing issues and comparisons normalizing. JORDAN: Let's break down the segments because there were some real divergences. Life Sciences Solutions was the star with 13% reported growth, though only 1% organic. That was driven by their bioproduction business having "another quarter of excellent organic growth," as CFO Stephen Williamson put it. ALEX: Meanwhile, Analytical Instruments was flat on revenue with organic declining 2%. This is the ongoing story we've been hearing across the industry - weak academic and government spending, especially in the US and China. Margins in that segment got hit hard, down 250 basis points to 20.7%. JORDAN: Ouch. And a lot of that margin pressure was from tariffs and foreign exchange headwinds. Williamson quantified the tariff This episode includes AI-generated content.

UnitedHealth Q1 2026 Earnings Analysis

**Beta Finch Podcast Script: United Health Group Q1 2026 Earnings** --- **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex. **JORDAN:** And I'm Jordan. Today we're diving into United Health Group's Q1 2026 results, and wow - this was a strong quarter across the board. **ALEX:** Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. **JORDAN:** Absolutely. So Alex, UNH just reported adjusted earnings per share of $7.23 for Q1, which was well ahead of expectations. They're now guiding for full-year adjusted EPS above $18.25. That's a pretty confident raise this early in the year. **ALEX:** It really is. And what I found interesting is that all four of their major business segments exceeded their internal plans. Revenue came in at $111.7 billion, which is 2% growth year-over-year. Now, that might seem modest, but remember - they've been very focused on disciplined pricing over growth this year. **JORDAN:** Right, and that strategy seems to be paying off. Their medical care ratio improved to 83.9% from 84.8% last year. CEO Andrew Witty was pretty clear that 2026 was about "margin recovery and product stability" rather than chasing membership growth. Sometimes you've got to take a step back to take two steps forward. **ALEX:** Exactly. And speaking of stepping back, they've made some major strategic moves. They completed their exit from all non-U.S. businesses and refreshed nearly half of their top 100 leadership roles. This is clearly a company that's refocusing on its core strengths. **JORDAN:** The OptumHealth story is particularly interesting here. They reported $1.3 billion in adjusted earnings, which was significantly higher than expected. CFO Wayne DeVeydt mentioned that all segments exceeded their internal plans, but OptumHealth really stood out. **ALEX:** What caught my attention was how they're improving their value-based care model. Krista Nelson from OptumHealth gave a great example - in their West Region, they increased clinical reviews by over 50% and saw a 35% reduction in skilled nursing facility admissions compared to last year. That's the kind of operational improvement that directly impacts the bottom line. **JORDAN:** And it makes sense from a patient care perspective too. They're serving over 20 million people in their OptumHealth care models, with 4 million in fully value-based arrangements. The research they cited showed 24% fewer hospital admissions and 29% fewer ER visits for patients in value-based care versus traditional Medicare. **ALEX:** Now let's talk about the elephant in the room - medical cost trends. This has been a big concern for the entire managed care industry. Tim Noel, who runs UnitedHealthcare, said trends are "progressing in line with expectations" and they're seeing "modest favorability in government programs." **JORDAN:** That's key because they've been dealing with elevated medical trends running around 7-8% in Medicare Advantage, and they priced for about 10% increases coming into 2026. If trends are coming in a bit better than expected, that's a real positive for margins going forward. **ALEX:** Let's pivot to their AI strategy because this is where things get really interesting for the long term. They're investing nearly $1.5 billion in AI-related initiatives in 2026. That's not just throwing money at the latest tech trend - they're being very strategic about it. **JORDAN:** Sandeep Dadlani broke down how they're spending that $1.5 billion - about a third goes to software products and platforms, accelerating OptumInsight's transition to AI-first services. The other two-thirds is spread across core processes throughout the company. **ALEX:** They launched "Avery," a generative AI chatbot for member questi This episode includes AI-generated content.

Abbott Laboratories Q1 2026 Earnings Analysis

**BETA FINCH PODCAST SCRIPT** --- **ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm here with my co-host Jordan to dive into Abbott Laboratories' Q1 2026 earnings call. Jordan, this was a pretty significant quarter for Abbott - they just closed their acquisition of Exact Sciences back in March. **JORDAN**: Absolutely, Alex. And before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. **ALEX**: Thanks for that reminder. So let's talk numbers first. Abbott reported adjusted earnings per share of $1.15 for Q1, which was right in line with their guidance despite some headwinds. Revenue-wise, they're now reporting what they call "comparable growth" of 3.7%, which includes Exact Sciences in both current and prior year numbers. **JORDAN**: That comparable growth metric is really interesting, Alex. CEO Robert Ford explained they're doing this to give investors a cleaner apples-to-apples view of the combined business. It's similar to what they did during COVID when they separated out COVID sales, or when they acquired St. Jude. The goal is transparency. **ALEX**: Right, and looking forward, they've updated their full-year guidance to 6.5% to 7.5% comparable sales growth. But here's what caught my attention - their adjusted EPS guidance midpoint dropped from $5.68 to $5.48. That $0.20 dilution is directly from the Exact Sciences acquisition, which was expected. **JORDAN**: Let's break down the business segments because there were some really interesting dynamics. Medical Devices was the star performer with 8.5% growth. The Electrophysiology business grew 13%, and get this - they had earlier-than-planned approvals for two new pulsed field ablation catheters. **ALEX**: Those PFA catheters are a big deal, Jordan. The Volt PFA catheter helped drive 14% growth in the U.S., while the TactiFlex Duo catheter contributed to mid-teens growth in Europe. Ford seemed pretty bullish about acceleration in the EP business as these launches broaden. **JORDAN**: And speaking of acceleration, the continuous glucose monitoring business had some interesting dynamics. CGM sales were $2 billion but only grew 7.5% due to an international tender delay and some tough comparisons from last year's shelf restocking. But management expects a return to double-digit growth in Q2. **ALEX**: That's a key point. During the Q&A, Ford was asked about concerns that the CGM market might be saturated. His response was fascinating - he said they estimate 70 to 80 million people globally should be on CGM, but the current market is only 10 to 12 million people. That's massive underpenetration. **JORDAN**: He also mentioned some upcoming catalysts, including expected CMS coverage for type 2 non-insulin patients, which could add close to 10 million people who currently don't have coverage. Ford was very clear he hadn't baked that into guidance, so it could be upside if it materializes. **ALEX**: Now let's talk about the Exact Sciences integration. This was really the elephant in the room. Ford named Jake Orville to lead that business, reporting directly to him. The Cologuard business grew 13% on a comparable basis, with mid-teens growth of the core Cologuard product. **JORDAN**: What struck me was Ford's long-term vision here. He doesn't see this as just a one-product deal, but as a beachhead into the entire cancer diagnostics space - screening, therapy selection, and MRD testing. He pointed out that about 50 million Americans aren't up to date with colorectal cancer screening. **ALEX**: And internationally, Ford said it's very underpenetrated. Abbott brings established regulatory and distribution relationships that could really accelerate international expansion. He even mentioned traveling to This episode includes AI-generated content.